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To study the role of nitric oxide (NO) in lung metastasis of
breast carcinoma, we isolated two cell clones (H and J)
from the parental EMT-6 murine breast carcinoma cell
line, based on their differential NO production. In vitro,
EMT-6J cells, but not EMT-6H cells, constitutively
expressed inducible NO synthase (NOS II) and secreted
high levels of NO. IL-1b increased NO production in both
clones, and TNF-a had a synergistic effect on IL-1b-induced
NO production, but NO production by EMT-6J cells
was always higher than by EMT-6H cells. Proliferation,
survival and adhesion to lung-derived endothelial cells of
both clones were similar and were not affected by NO.
In vivo, both clones similarly located in the lungs of syn-
geneic mice 48 h after injection. However, EMT-6H cells
were significantly more tumorigenic than EMT-6J cells as
assessed at later time points. Injection of EMT-6J
cells and simultaneous treatment of mice with aminogua-
nidine (AG), a NOS II inhibitor, significantly increased
tumour formation. Injection of EMT-6H and EMT-6J
cells into NOS II-deficient mice resulted in a significant
survival increase as compared with wild-type animals.
Simultaneous administration of AG increased the death
rate of NOS II-deficient mice injected with EMT-6J
cells. These results demonstrate that: (i) NO does not
influence the early stages of tumour metastasis to the
lungs and (ii) NOS II expression in tumour cells reduces,
while NOS II expression in host cells enhances, tumour
nodule development. In conclusion, the cellular origin
and the local NO production are critical in the metastatic
process.
Introduction
The metastatic and growth potential of tumours is dependent
on the ability of circulating tumour cells to escape immune
responses, to adhere to endothelium, to extravasate and to
survive and grow in the target tissue. Nitric oxide (NO) is
a potent bioactive molecule produced by nitric oxide syn-
thase (NOS) enzymes. NO has been involved in numerous
physiological as well as pathological mechanisms such as
vasodilatation and inflammation. Demonstration of NO and
of inducible NOS (NOS II) expression in various solid
tumours and their metastases as well as in tumour cell
lines has suggested that this biological mediator may parti-
cipate in tumour survival and metastatic process. However,
conflicting results have been reported that may reflect a
more complex effect of NO than anticipated previously.
NO has been shown to decrease the expression of adhesion
molecules such as VCAM-1, ICAM-1, E-selectin that med-
iate interactions between tumour cells and host endothelial
cells (1--3). Furthermore, NO could impair tumour cell
extravasation and extracellular matrix (ECM) degradation
through inhibition of the secretion of matrix metalloprotei-
nases (MMPs) such as MMP-2 (4). Sustained overproduction
of NO may also enhance tumour cell susceptibility to apop-
tosis and death through the expression or activation of cell
death effectors such as p53 (5) or caspases and Fas (6).
These observations suggest a negative role of NO on tumour
progression or metastasis. However, protumorigenic effects
of NO have also been reported. NO vasodilatory and angio-
genic properties were associated with tumour growth and
may participate in tumour-induced immunosuppression by
decreasing proliferation and activation of lymphocytes (7).
The tumour microenvironment may also influence tumour
development as low NO concentrations may favour angio-
genesis and tumour growth while higher NO concentrations
may be cytostatic (8,9).
Breast tumours mainly metastasize to the lungs and
bones (10). In the lungs, mammary tumour cells are
retained in capillaries (11) where they adhere to endothelial
cells through specific adhesion molecules such as integrins,
selectins and N-cadherin. Tumour cells may then invade
the lung parenchyma following proteolysis of the ECM
through secretion of proteolytic enzymes such as MMP-2
(12). In previous work we had observed high levels of
NOS II reactivity in malignant human breast cancer,
which negatively correlated with proliferation and tumour
grade (13). In order to define in more detail the role of NO
in the metastatic process, we developed an experimental
model consisting of high and low NO-producing murine
breast carcinoma cell clones derived from the parental
mammary EMT-6 tumour cell line (14). The in vitro pro-
liferation and adhesive properties to murine lung-derived
endothelial cells were determined. The implication of
tumour-derived and of host-derived NO in the metastatic
potential of both clones to the lungs was further investi-
gated in syngeneic NOS II-deficient mice. How the cellular
origin of NO may differentially regulate tumour metastasis
is discussed.
Abbreviations: AG, aminoguanidine; EMEM, Eagle's minimal essential
medium; MMP, matrix metalloproteinase; MTT, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide; NO, nitric oxide; NOS II, inducible nitric
oxide synthase.
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Materials and methods
Cell selection
The cell clones EMT-6H and EMT-6J, syngeneic to Balb/c mice, were
obtained by limiting dilution from the EMT-6 parental breast tumour cell
line (kindly provided by Dr M.Lepoivre, CNRS, Orsay, France). They were
selected based on NO production: EMT-6J released significant levels of NO
while EMT-6H did not. Cells were grown as monolayers at 37C in Eagle's
minimal essential medium (EMEM, Eurobio, Les Ulis, France) supplemented
with 10% fetal calf serum (FCS Hyclone, Biovalley, Marne la Vallee, France)
and 2 mM L-glutamine (Biowhittaker, Fontenay sous Bois, France), in a
humidified atmosphere (5% CO2 and 95% air). Cultures were tested monthly
for Mycoplasma contamination with the mycotect kit (Life Technologies,
Cergy Pontoise, France) and before each in vivo experiment.
Cell culture protocols
For cytokine-stimulated NO production, EMT-6H and EMT-6J cells (5  104
cells/well) were grown for 24 h in 96-well plates then treated for another 24 h
with the cytokines IL-1b (Sanofi, Labege, France), TNF-a and IFN-g (Insight
Products, UK). When indicated, cells were grown for 24 h with 0.5 mM
aminoguanidine (AG) (Sigma-Aldrich, Lyon, France). For proliferation
assay, EMT-6H and EMT-6J cells (5  103 cells/well) were grown in 96-
well plates for 48 h in the presence or not of 0.5 mM AG. Proliferation was
assessed after 48 h by incorporation of [3H]thymidine (1 mCi/well, Amersham
Pharmacia, Buckinghamshire, UK) for the last 2 h of incubation. The cells
were washed twice with PBS and adherent cells were lysed in 1 N NaOH for
2 h at 60C. Radioactivity was determined by liquid scintillation spectrometry
(LKB Rackbeta LKB Wallac, Turku, Finland). Spontaneous cell death was
measured as described previously (15). Briefly, 2.5 105 EMT-6H or EMT-6J
cells were seeded in 6-well plates and incubated overnight at 37C with 1
mCi [3H]thymidine. The labelled cells were detached and seeded (25 
103 cells/ml, 200 ml/well) in a 96-well plate for 48 h. Cells were lysed and
cell-associated radioactivity determined as above. For the determination of
cellular ability to adhere to plastic (15,16), EMT-6H or EMT-6J cells
(104 cells/well) were seeded in 96-well plates and incubated at 37C for 48
h. Cells were washed with PBS, fixed in methanol, stained with 1% methylene
blue for 30 min, dissolved in 0.1 N HCl and absorbance was measured at 620
nm in a multi-well microtitre plate reader (Anthos, Labtech Instruments,
Emerainville, France). Alternatively EMT-6H or EMT-6J cells (5 
103 cells/well) were seeded in 96-well plates and incubated at 37C for 48 h.
Cells were washed with 0.9% NaCl, stained with neutral red for 2 h, fixed in a
0.4% formalin--1% CaCl2 solution and extracted in 1% acetic acid in 48%
ethanol. Absorbance was measured at 540 nm in a multi-well microtitre plate
reader. Cellular survival was assessed using a 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) assay (17). Briefly, EMT-6H or
EMT-6J cells (5  103/well) were seeded in 96-well plates and incubated at
37C for 48 h. Then 10 ml of 5 mg/ml MTT in PBS were added for 2 h.
Formazan crystals were dissolved in 200 ml DMSO and absorbance was
measured at 570 nm in a multi-well microtitre plate reader.
Determination of NO production
NO production was determined as nitrite and nitrate accumulation in cell
culture media using the Griess microassay (18). Briefly, nitrates were reduced
to nitrites using nitrate reductase (Diffchamb, France) and 100 ml of reduced
supernatants were added to 100 ml Griess reagent (0.5% sulfanilamide and
0.05% naphthylethylenediamine in 2.5% phosphoric acid). Absorbance was
measured at 540 nm in a multi-well microtitre plate reader and nitrite concen-
tration was calculated by comparison with a standard sodium nitrite solution.
NOS II RT--PCR analysis
Total RNA was prepared using the NucleospinÒ RNA II kit (Macherey-Nagel,
Hoerdt, France) according to the manufacturer's protocol. 550 ng RNA were
used for NOS II amplification and 125 ng for GAPDH amplification. RT--PCR
was performed using the two-enzyme Access RT--PCR system (Promega,
Charbonniere, France). First strand cDNA synthesis was carried out at 48C
for 45 min, then the AMV reverse transcriptase was inactivated and the
RNA--cDNA hybrid denatured by a 2-min incubation at 94C. Amplifications
were performed using 25 cycles as follows: 94C/30 s, 63C/30 s, 68C/1 min.
The sequences of NOS II RNA, located between 1379 and 1877, and
GAPDH RNA, located between 256 and 750, were amplified using the
following sense and antisense primers: 50-CCAGTGTCTGGGAGCAT-
CACCCCTG-30 and 50-GAACTGAGGGTACATGCTGGAGCC-30 (NOS II)
and 50-GCCCATCACCATCTTCCAGGAGCG-30 and 50-GGGGTAGGAA-
CACGGAAGGCCATGC-30 (GAPDH). The PCR products migrated as a
single band of 498 bp for NOS II and of 504 bp for GADPH.
In vitro adhesion of tumour cell clones to lung-derived endothelial cells
The End p23 murine pulmonary endothelial cell line and the adhesion assay
have been described previously (19,20). Briefly, sub-confluent End p23 cells
were cultured for 24 h in 48-well microtitre plates and washed twice with PBS
immediately before the adhesion assay. EMT-6H and EMT-6J tumour cells
were labelled with 0.4 mCi/ml of [3H]thymidine for 16 h and added (105 cells/
well) to confluent End p23 monolayers in Dulbecco's Modified Eagle's med-
ium (DMEM) without FCS. After 30, 60 or 180 min incubation at 37C non-
adherent cells were removed by washing three times with DMEM. Adherent
cells were dissolved overnight in 0.1% SDS/0.1 M NaOH and radioactivity
was quantified by liquid scintillation spectrometry. Adhesion (%) was deter-
mined as the ratio of the c.p.m. of adherent cells to the c.p.m. of total (adherent
and non-adherent) cells  100.
Maintenance and genotyping of NOS II-deficient mice
C57BL/6129SvEv mice with a targeted disruption of the NOS II gene (NOS
IIÿ/ÿ) (21) were obtained from Dr Y.Courtois (INSERM U450, Paris,
France) and mated in our animal facility with Balb/c wild type mice (/)
(Charles River Laboratories, l'Arbresle, France) for nine generations to pro-
duce heterozygous NOS II-deficient mice (/ÿ). Heterozygous NOS II-defi-
cient mice were mated to produce NOS II ÿ/ÿmice. Genotyping to confirm the
presence or absence of the NOS II gene was performed using PCR of DNA
from tail biopsies. Samples were incubated overnight at 54C in lysis buffer
[100 mM Tris, pH 8.5, 5 mM ethylene diamine tetraacetic acid (EDTA),
200 mM NaCl, 0.2% SDS and 100 ml proteinase K (10 mg/ml)]. After centri-
fugation, the DNA was purified by two cycles of isopropanol precipitation and
phenol--chloroform extraction, precipitated and washed in 70% cold ethanol
and resuspended in 100 ml of Tris--EDTA (10 mM Tris, pH 7.5, 1 mM EDTA,
pH 8). DNA products were amplified by 30 cycles of PCR (94C/30 s, 60C/30 s
and 72C/45 s) using Taq DNA polymerase (Eurobio, Les Ulis, France). The
sequence of the NOS II gene located between ÿ499 and 161 was amplified
using the following sense and antisense primers: 50-GCACAGCCCATCCA-
CTATTCT-30 and 50-GAGTGAACAAGACCCAAGCGT-30. To identify the
NOS II /ÿ and ÿ/ÿ mice, the amplification of the neo resistance gene was
performed using the sense and antisense oligonucleotides: 50-ATCGACAA-
GACCGGCTTCCATCCGA-30 and 50-TCAGCGCAGGGGCGCCCGGTCT-
TT-30, which amplify a 475 bp PCR product. The amplified products were
electrophoresed in 1% agarose gel containing ethidium bromide.
Tumour nodule induction in lungs
Animal experiments were performed using 8--9-week-old female wild-type
mice and NOS II-deficient (NOS II KO) female Balb/c mice. All experimental
protocols had been approved by the Ethics Committee of the University of
Dijon, France. EMT-6H or EMT-6J cells in exponential growth phase were
harvested, dissociated to produce single-cell suspensions, washed and sus-
pended in culture medium. Cell viability was determined by trypan blue
exclusion and only cell suspensions with >90% viability were used for animal
experimentation. 100 000 cells in 0.1 ml of EMEM were injected into the
lateral tail vein of non-anaesthetized mice. The mice were killed after 35 days.
Killed and spontaneously dead mice were autopsied and pulmonary nodules
were counted. AG-treated mice received intraperitoneal (i.p.) injections of
50 mg/kg AG, an inhibitor of NOS II activity (22), twice a day, throughout
the experiment.
111Indium oxine labelling procedure and location of 111In-labelled cells
in mice
EMT-6H or EMT-6J cells [2  106 cells in 0.5 ml EMEM--HEPES
(Biowhittaker, Fontenay sous Bois, France)] were incubated with 85 mCi of
111indium oxine (Mallinckrodt, Les Ulis, France) for 15 min at 37C as
described previously (23). Cells were washed three times with EMEM--HEPES
to remove free 111In. Cell-bound 111In radioactivity was measured using a
gamma counter (MR 480 Packard, Packard Bioscience, Meriden, CT).
Labelled cells (105 cells) were injected in the tail vein of mice. Radioactivity
location was determined in anaesthetized animals using a single-head Basicam
gamma camera (Siemens Medical System, Erlangen, Germany) for image
acquisition consisting of 30 images of 1 min each. The images were analysed
with the SMV-GE Vision processing system (Sopha Medical Vision-General
Electric, Buc, France). Thorax and abdomen were manually defined and the
radioactivity in the two regions was calculated based on a summed image.
Mice were killed at different time points after injection, and heart, liver and
lungs were collected, washed with 0.9% NaCl and their 111In content was deter-
mined in an automatic well counter (MR 480 Packard, Packard Bioscience).
Data analysis
Data are presented as mean  SD. Statistical differences were determined by
unpaired Student's t test or x2 test. Survival rates were calculated using the
Kaplan--Meier method, according to tumour cell clone or treatment. Curves
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were compared using the log rank test. Survival rates were computed using the
Stata package (Stata 1999, College Station, TX). Differences were considered
significant for P  0.05.
Results
Two cell clones were isolated by limiting dilution from the
parental EMT-6 murine mammary carcinoma cell line and
selected from their production of NO (measured as the accu-
mulation of nitrites plus nitrates in the culture supernatant).
EMT-6H cells produced NO levels below the detection thresh-
old whereas EMT-6J cells released up to 5 mM NO2
ÿ  NO3ÿ/
48 h/5  104 cells (Table I). EMT-6J cells, but not EMT-6H
cells, expressed NOS II mRNA (Figure 1) as detected by
RT--PCR amplification. IL-1b increased NO production
while TNF-a and IFN-g had no effect (Table I). Synergistic
effect was observed with IL-1b plus TNF-a but not with IL-
1b plus IFN-g or TNF-a plus IFN-g (Table I). In all treat-
ments, NO released in response to cytokines by EMT-6J cells
was always higher than that of EMT-6H cells (P 5 0.001,
Table I).
Spontaneous as well as induced NO production was inhib-
ited by 0.5 mM AG (Table I). In vitro proliferation, sponta-
neous cell death, cellular ability to adhere to plastic and
cellular metabolic activities were similar for both cell clones
and were not affected by AG. These results excluded a direct
role of NO on the growth and survival of EMT-6H or EMT-6J
tumour cells in vitro. In vitro proliferation was measured by
[3H]thymidine incorporation, EMT-6H cells with or without
AG: 266  103  13  103 and 234  103  24  103 c.p.m.,
respectively, and EMT-6 J cells with or without AG: 253 
103  32  103 and 239  103  14  103 c.p.m., respec-
tively. Spontaneous cell death was measured by [3H]-thymi-
dine release, EMT-6H cells with or without AG: 100  103 
7  103 and 96  103  9  103 c.p.m., respectively, and
EMT-6J cells with or without AG: 112  103  15  103 and
134  103  55  103 c.p.m., respectively. Cellular ability to
adhere to plastic was determined by methylene blue assay,
absorbance at 620 nm, EMT-6H cells with or without AG: 1.63
0.21 and 1.46  0.17, respectively, and EMT-6 J cells with or
without AG: 1.80  0.09 and 1.77  0.08, respectively. Cel-
lular metabolic activities were assessed by neutral red exclu-
sion and MTT reduction. Neutral red exclusion, absorbance at
540 nm, EMT-6H cells with or without AG: 0.82  0.05 and
0.79  0.04, respectively, and EMT-6J cells with or without
AG: 0.82 0.1 and 0.80 0.04, respectively. MTT reduction,
absorbance at 570 nm, EMT-6H cells with or
without AG: 0.71  0.09 and 0.78  0.06, respectively, and
EMT-6J cells with or without AG: 0.65  0.05 and 0.77 
0.07, respectively.
For tumour cell location in organs after i.v. injection, the
tumour cells were labelled with 111indium oxine. In vitro
proliferation and survival of labelled EMT-6H and EMT-6J
cells were similar for both clones, as 480% of labelled H or J
cells were alive after 48 h culture. 100 000 of 111In-labelled
cells were injected in the tail vein of syngeneic mice and
tumour cell location was evaluated by whole mice scintigraphy
images, within 48 h, both clones located mainly in the thorax.
As a control, injection of cell-free 111indium oxine in mice
resulted in a homogenous distribution over the whole mice
(data not shown). The organs of mice injected with 111In-
labelled EMT-6H or EMT-6J cells were excised at different
times and radioactivity was quantified. Three independent
experiments showed that 48 h after tumour cells injection
~40% of total injected radioactivity was retained in the lungs
for both cell clones. The radioactivity ratio (mice injected with
EMT-6H to EMT-6J cells) measured in the lungs was stable for
48 h (Figure 2), indicating that short-term tumour cell location
in the lungs was independent of clones. Radioactivity was also
detected in the liver (results not shown), but as tumour nodules
were never observed in this organ, liver-associated radioactiv-
ity was attributed to accumulated dead cells.
As in vivo experiments showed that both tumour cell clones
located in the lungs within 48 h, we evaluated the in vitro
adhesive properties of EMT-6H and EMT-6J cells on murine
lung-derived p23 endothelial cells. Short-term (30 or 60 min)
and long-term (3 h) adhesion assays were performed (Figure 3)
and showed that both EMT-6H and EMT-6J cells adhered
similarly to lung-derived endothelial cells in vitro. Taken
together these results suggest that tumour-derived NO was
not critical in one of the first steps of tumour nodule formation,
the initial arrest of breast tumour cells in the pulmonary
endothelium.
Table I. Spontaneous and cytokine-stimulated NO production by
EMT-6H and EMT-6J cells
NO production (NO2
ÿ  NO3ÿ) (mM) EMT-6H cells EMT-6J cells
Medium 0.29  0.20 4.32  0.85
Medium  AG 0.61  0.10 0.77  0.33y
IL-1b 11.84  1.53 29.07  3.05
TNF-a 0.69  0.53 4.11  0.51
IFN-g 0.05  0.17 4.39  0.53
IL-1b  TNF-a 24.03  0.74 40.49  1.20
IL-1b  IFN-g 11.72  1.49 29.67  2.80
TNF-a  IFN-g 0.52  0.31 2.07  0.97
IL-1b  IFN-g  TNF-a 18.71  3.19 34.01  5.70
IL-1b  IFN-g  TNF-a  AG 0.56  0.25# 0.10  0.53
Cells were grown for 24 h then treated with cytokines for another 24 h.
Cytokines were used at the following concentrations, IL-1b, 55 pg/ml;
TNF-a, 4.5 ng/ml and IFN-g, 500 pg/ml. NO production was measured as
nitrate  nitrite accumulation in culture media. Results are the means of
four independent experiments. The statistical significance of the data was
analysed using an unpaired Student's t test. NO production by EMT-6J
versus EMT-6H cells were always significantly higher (P 5 0.001) except
with TNF-a  IFN-g.
P 5 0.001, NO production of stimulated EMT-6H or EMT-6J cells
versus unstimulated controls.
#P 5 0.001, NO production of stimulated EMT-6H or EMT-6J cells in
the absence versus in the presence of AG.
yP 5 0.001, NO production of unstimulated EMT-6J in the absence versus
in the presence of AG.
GAPDH 
NOS II 
EMT-6H EMT-6J
Fig. 1. EMT-6J cells but not EMT-6H cells express NOS II mRNA Cells
were grown to sub-confluence then total RNA was prepared for RT--PCR
amplification. The results of one representative experiment out of three
are shown.
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However, long-term survival experiments showed a signifi-
cant difference between mice injected with EMT-6H or EMT-
6J cells. Twenty-seven out of twenty-nine mice (93%)
injected with EMT-6H cells died within 35 days, while only
eight out of 29 mice (28%) injected with EMT-6J cells died
before day 35 (P5 0.0001, Figure 4). In contrast, 19 out of 30
mice (63%) injected with EMT-6J cells and receiving AG
(50 mg/kg i.p. injected twice a day for 35 days), an inhibitor
of NOS II activity, died within 35 days (Figure 4, P  0.0071,
mice treated with AG compared with untreated mice). On the
other hand, the life span of mice injected with EMT-6H cells
did not change when mice were treated with AG. EMT-6H
cells induced the formation of numerous tumour nodules in the
lungs of all the injected mice (Table II). In contrast, the
number of mice with pulmonary tumour nodules was lower
and the number of nodules per lung was lower (P 5 0.001) in
the EMT-6J group (Table II). AG treatment increased the
number of tumour nodule-bearing mice and decreased the
number of tumour nodules per lung in mice injected with
EMT-6J cells (P 5 0.01) but had no significant effect in
mice injected with EMT-6H cells (Table II). Therefore, there
was a relationship between the life span of mice and the
number of tumour nodules they bore.
As i.p. injection of AG would result in inhibition of NOS II
activity both in tumour cells and in host cells, these experi-
ments did not allow to evaluate the contribution of host-
derived NO in the formation of tumour nodules in the lungs.
To further investigate the respective roles of tumour cell-
derived or host-derived NO, we used NOS II-deficient mice.
Twenty-four out of twenty-seven (90%) wild-type mice
injected with EMT-6H cells died within 35 days, while 16
out of 27 (60%) NOS II-deficient mice (Figure 5A, P 
0.0006) died within the same time. Seven out of twenty-eight
(25%) wild-type mice injected with EMT-6J cells, while two
out of 30 (7%) NOS II-deficient mice (Figure 5B, P  0.06)
died within 35 days. The number of tumour nodules in the
lungs of NOS II-deficient mice injected with EMT-6H was
lower than in wild-type mice (P  0.016). In mice injected
with EMT-6J cells, the number of tumour nodule-bearing
mice and the number of tumour nodules per lung were lower
in NOS II-deficient mice than in wild-type mice (P 5 0.01)
(Table III). Taken together, these results demonstrated that
tumour growth and mice survival was increased in NOS II-
deficient mice independently of the cell clone injected.
None of the nine NOS II-deficient mice injected with EMT-
6J cells died within 35 days while three out of the nine mice
receiving AG died within the same time (P 5 0.05, Figure 6).
The number of tumour nodule-bearing mice and the number of
tumour nodules per lung increased in AG-treated mice (data
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Fig. 2. 111Indium-labelled EMT-6H or EMT-6J tumour cells location in the
lungs was independent of clones EMT-6H and EMT-6J cells were labelled
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Fig. 3. Adhesion of EMT-6H and EMT-6J cells to murine lung-derived
endothelial cells. Adhesion of [3H]thymidine-labelled EMT-6H cells or
EMT-6J cells to endothelial cells was measured in vitro after either
30 (shaded bar), 60 (clear bar) or 180 min (black bar). Results are expressed
in per cent of adherent cells and are the means of triplicate wells SD. Three
independent experiments were performed. No statistically significant
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Fig. 4. Survival of mice injected with EMT-6H cells or EMT-6J cells. Mice
were injected in the tail vein with 105 EMT-6H cells or EMT-6J cells and
mice survival was determined. AG was injected i.p. twice a day. Surviving
mice were killed 35 days after the injection of tumour cells.
Table II. Counting of tumour nodules in the lungs of mice injected either
with EMT-6H or EMT-6J cells
Number of
nodules
per lung
Number of mice bearing lung tumour nodules/number of
mice injected
EMT-6H
cells
EMT-6J
cells
EMT-6H cells
and treated
with AG#
EMT-6J cells
and treated
with AGy
0 0/29 8/29 0/26 5/30
1--10 0/29 9/29 0/26 1/30
11--50 3/29 6/29 2/26 10/30
51--100 3/29 0/29 4/26 2/30
>100 23/29 6/29 20/26 12/30
The number of nodules in the lungs of mice injected in the tail vein with either
EMT-6H or EMT-6J cells, and treated or not treated with AG, was counted.
The cumulative data are from the autopsies of spontaneously dead mice or
mice killed 35 days after tumour cell injection. The statistical significance
of the results was analysed using a x2 test.
P 5 0.001 EMT-6J cells compared with EMT-6H cells.
#n.s. EMT-6H cells  AG compared with EMT-6H cells.
yP 5 0.01 EMT-6J cells  AG compared with EMT-6J cells.
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not presented because of marginal statistical significance).
Therefore, NO production by tumour cells prevented tumour
progression.
Discussion
It was shown previously that NOS II is heterogenously
expressed in human breast cancer (24). NOS II expression
has been demonstrated using immunohistochemistry in mam-
mary tumour cells (13,24--26), or in cancer stroma (25,27).
Moreover, the evaluation of NOS II activity in human breast
cancer gave inconsistent results, being either negatively corre-
lated (13,25), positively correlated (26) or not correlated (24)
to tumour grade. The role of NO in breast tumour progression
is also controversial: NO may either favour metastasis by
promoting cancer cell migration, invasiveness and angiogen-
esis (28--30,34), or antagonize metastasis by decreasing the
expression of adhesion molecules (1--3).
To investigate whether the cellular origin of NO may affect
the metastatic potential to the lungs of breast tumour cells we
investigated first the role of tumour-derived NO. Toward this
goal, we subcloned low and high NO-producing murine breast
carcinoma cell lines from the parental EMT-6 cells (14). The
results indicated that NO produced by tumour cell was not
implicated in vitro in tumour cell proliferation, survival or
adhesion to murine lung-derived endothelial cells. Thus, both
EMT-6H and EMT-6J cells are NO resistant. In vivo, tumour
cell-derived NO was not involved in the localization of tumour
cells in the lungs of syngeneic mice within 48 h following i.v.
injection. These data indicated that NO produced from tumour
cells was not a determining factor in the initial arrest of tumour
cells in the lung capillaries. However, in vivo, in the long term,
the low NO-producing tumour cells (EMT-6H cells) devel-
oped more tumour nodules in the lungs than the high NO-
producing tumour cells (EMT-6J cells). The death rate of mice
injected with low NO-producing cells was also higher than that
of mice injected with high NO-producing cells. These results
suggested that NO may be protective at later metastatic stages
than the initial tumour cells arrest in the lungs. In long-term
in vivo experiments, inhibition of NOS II activity by AG (22) in
tumour cells and in animals increased the death rate, the
number of tumour-bearing mice and the number of nodules
in mice injected with EMT-6J cells, but not in mice injected
with EMT-6H cells, which rules out a toxic effect of AG. Thus,
in NOS II-expressing mice, NO was protective against metas-
tasis. In NOS II-deficient mice, the development in the lungs
of tumour nodules was decreased and mice survival increased,
whatever the tumour cell clone. These results indicate that
NOS II expression by the host cells favours metastasis. Thus,
in our model, NO had opposite effects depending on whether it
was tumour cell-derived or host-derived. In agreement with
our results, it was shown that NOS II disruption in mice
enhanced metastasis of NO-sensitive murine ovarian sarcoma
cells (31). And NOS II disruption in mice suppressed metas-
tasis of NO-resistant murine melanoma cells, which was
dependent on down-regulation of VEGF in melanoma
metastases (32).
Thomsen et al. (33) have reported that NOS II inhibition
by 1400W reduced the size of subcutaneous (s.c.) EMT-6
tumours. Thus, NO functions in the growth of s.c. tumour are
different from its role in tumour metastasis to the lungs.
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Fig. 5. Survival of wild-type (WT) mice (circles) and NOS II KO mice
(diamonds) injected with EMT-6H cells or EMT-6J cells. Mice were injected
in the tail vein with 105 EMT-6H (A) or EMT-6J (B) cells and mice survival
was determined. Surviving mice were killed 35 days after the injection
of tumour cells.
Table III. Counting of tumour nodules in the lungs of wild-type and
NOS II-deficient mice injected either with EMT-6H or EMT-6J cells
Number of
nodules
per lung
Number of mice bearing lung tumour nodules/number of
mice injected
EMT-6H cells EMT-6J cells
Wild type
mice
NOS II-
deficient mice
Wild type
mice
NOS II-
deficient mice#
0 0/27 0/27 0/28 4/30
1--10 1/27 9/27 16/28 23/30
11--50 1/27 4/27 6/28 3/30
51--100 5/27 2/27 0/28 0/30
>100 20/27 12/27 6/28 0/30
The number of nodules in the lungs of mice injected in the tail vein with either
EMT-6H or EMT-6J cells was counted. The cumulative data are from the
autopsies of spontaneously dead mice or mice killed 35 days after tumour cell
injection. The statistical significance of the results was analysed using a
x2 test.
P  0.016 wild-type mice compared with NOS II-deficient mice.
#P 5 0.01 wild-type mice compared with NOS II-deficient mice.
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Fig. 6. Survival of NOS II KO mice injected with EMT-6J cells. Mice were
injected in the tail vein with 105 EMT-6J cells and mice survival was
determined. AG was injected i.p. twice a day or not. Surviving mice were
killed 35 days after the injection of tumour cells.
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Another explanation of this disagreement is certainly the het-
erogeneity of the EMT-6 parental cells. Using two mammary
tumour cell lines differing in their metastatic phenotype,
Orucevic et al. (34) showed that NO promoted tumour cell
invasiveness. This metastasis-promoting effect of NO released
by tumour cell was attributed to NOS III, which produces only
low amounts of NO, comparable with the levels secreted by
EMT-6H cells. Our present results demonstrated that low
levels of tumour-derived NO promoted tumour development.
Thus, it appears that not only the cellular origin of NO, but also
the level of NO secretion is crucial for its biological effects
in cancer.
The mechanisms involved in NO-dependent reduction of the
development of tumour nodules in the lungs are not yet eluci-
dated. NO has been shown to decrease leukocyte adhesion to
endothelial cells (35--37) through inhibition of the expression
of adhesion molecules, either on endothelial cells (1) (such as
VCAM-1) or on leukocytes (38) (such as E-selectin or ICAM-
1). In vitro NO was shown to up-regulate the expression of
ICAM-1 on tumour cells (3) and to increase the adhesion of
tumour cells to endothelial cells (39). However, in vivo only
few data are available. Our in vitro and short-term in vivo
experiments did not support a NO-dependent adhesion of
breast cancer cells to pulmonary endothelial cells. NO was
also shown to inhibit platelet aggregation (40), which pro-
motes metastasis. The regulating role of NO in inflammatory
response could also be involved. In support of this possibility,
we have shown previously that NO sensitizes colon tumour
cells to Fas-mediated cell death in vitro (6) implying the
involvement of NK or T lymphocytes. However, our studies
do not exclude the possibility that phenotypic differences
between the EMT-6H and EMT-6J cells other than NO-produ-
cing ability, e.g. the degree of MMP expression, may have
added to the differences in their metastatic ability or mortality
in tumour-bearing hosts.
In conclusion, our results demonstrated: (i) that NOS II
expression by breast tumour cells reduces, while NOS II
expression by host cells enhances, tumour nodule development
in the lungs of syngeneic mice; (ii) that local NO concentration
is important in this process; and (iii) that NO is not decisive in
the initial arrest of breast tumour cells in lung capillaries, but is
critical in later stages of nodule development.
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